PT - JOURNAL ARTICLE AU - David Fiorella AU - Adam Arthur AU - Alan Boulos AU - Orlando Diaz AU - Pascal Jabbour AU - Lee Pride AU - Aquilla S Turk AU - Henry H Woo AU - Colin Derdeyn AU - John Millar AU - Andrew Clifton TI - Final results of the US humanitarian device exemption study of the low-profile visualized intraluminal support (LVIS) device AID - 10.1136/neurintsurg-2015-011937 DP - 2016 Sep 01 TA - Journal of NeuroInterventional Surgery PG - 894--897 VI - 8 IP - 9 4099 - http://jnis.bmj.com/content/8/9/894.short 4100 - http://jnis.bmj.com/content/8/9/894.full SO - J NeuroIntervent Surg2016 Sep 01; 8 AB - Introduction The low-profile visualized intraluminal support (LVIS) device is a new, braided, intracranial microstent designed for stent-assisted coiling.Objective To present the results of a single-arm, prospective, multicenter trial of the LVIS for treatment of wide-necked intracranial aneurysms.Methods 31 patients with unruptured, wide-necked (neck ≥4 mm or dome:neck ratio ≤2) intracranial aneurysms were treated with the LVIS device and bare platinum coils at six US centers (investigational device exemption G110014). Clinical follow-up was conducted at 30 days and 6 months. Angiographic follow-up was performed at 6 months. The primary safety endpoint was any major stroke or death within 30 days or major ipsilateral stroke or neurological death within 6 months. ‘Probable benefit’ was defined as ≥90% angiographic occlusion at 6 months. An independent core laboratory adjudicated the angiographic results. An independent clinical events committee adjudicated the clinical endpoints.Results Average aneurysm size was 7.2 mm (SD 3.8) and average neck width was 4.6 mm (SD 1.8). 68% of patients had a dome:neck ratio ≤2. LVIS placement was technically successful in 29/31 patients (93.5%). No primary safety endpoints occurred during the study (0%). No patient had a higher modified Rankin Score at 6 months than at baseline. 26/28 (92.9%) treated aneurysms with 6-month angiographic follow-up demonstrated ≥90% angiographic occlusion. 21/28 (75%) were completely occluded at follow-up.Conclusions The LVIS device facilitated the coil embolization of wide-necked intracranial aneurysms with high rates of technical success, an excellent safety profile, and very high rates of complete and near-complete occlusion at follow-up.Trial registration number NCT01541254.